NCT06564298View on ClinicalTrials.gov

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Stomach Neoplasms
Interventions
DRUG

Sintilimab

Sintilimab 200mg iv.gtt d1, every 21 days

DRUG

Ramucirumab

Ramucirumab 10mg/kg iv.gtt d1, every 21 days

DRUG

SOX/XELOX

SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER